|
Market Cap (25-Jun) $27,342,400 (1,032nd) |
Close (30-Jun) $0.008 |
Volume (30-Jun) 285,280 |
Shortsold (12-Dec) 6,497 (0.00%) (681st) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.09 |
EX1 released this announcement to the ASX on 16 April 2021, 9:36. The announcement is not marked as price sensitive, and is 17 page(s) in length and 2.31MB in size.
You can view all announcements from EX1 and see how they appear on a price chart on the announcements page.
At the date of this announcement, EX1 was 0.012% short sold according to ASIC data. It was ranked the 568th most shorted stock on the ASX. It remains ranked 681st as of the latest reported data (12 December 2022).
| Other Recent Announcements from EX1 | |
|---|---|
| Initial Director's Interest Notice - MD | 22 June 2023, 11:52 |
| Change of Director's Interest Notice - CB | 22 June 2023, 11:51 |
| Final Director's Interest Notice - JW | 22 June 2023, 11:50 |
| Investor Presentation - Delivering Transformative Medicines | 16 April 2021, 9:36 |
| Quarterly Activities Report and Appendix 4C | 16 April 2021, 9:25 |
| Trading Halt | 15 April 2021, 16:21 |
| Exopharm Shareholder Update - Revenue Focus in 2021 | 8 April 2021, 8:32 |
You must be logged in to post a reply.
Exopharm 